About
Twenty years translating biology into decisions
MyMetabolome is the independent scientific consulting practice of Giuseppe Astarita, Ph.D. I founded MyMetabolome to bring senior-level scientific expertise directly to the organizations that need it — without the overhead of a large consultancy. My work sits at the intersection of lipid biology, multi-omics mass spectrometry, and translational drug development.
Over two decades I have built omics platforms and biomarker programs from the ground up at Denali Therapeutics and Arkuda Therapeutics, advancing assets through proof-of-concept in Alzheimer's, Parkinson's, lysosomal storage disorders, frontotemporal dementia, and neuroinflammation. A particular focus has been lysosomal trafficking and its role in brain disease — including progranulin biology, GBA-related lipid dysregulation, and sphingolipid pathway alterations connecting lysosomal dysfunction to neurodegeneration. I have led CRO partnerships, shaped regulatory-facing evidence packages, and presented at Scientific Advisory Board (SAB) meetings.
My expertise extends well beyond neuroscience. I have applied multi-omics approaches to metabolic disorders (insulin resistance, hepatic steatosis, cardiometabolic disease), inflammation and immune biology (oxylipins, eicosanoids, endocannabinoid system), and nutrition and food science — areas interconnected at the level of lipid biology and metabolic pathway dysregulation.
A recurring thread in my career has been making methods travel between laboratories. At Waters Corporation I managed worldwide metabolomics and lipidomics programs spanning 100+ collaborations with KOL laboratories across academia, pharma, and industry, and led workshops and training sessions globally. At Metabolon I developed 20+ standardized biomarker panels and acted as scientific liaison for 20+ pharma, biotech, and academic clients. I have contributed multi-omics datasets to multi-site efforts including the Michael J. Fox Foundation LRRK2 Cohort Consortium, and I advise groups on core-facility workflows — SOPs, method standardization, and QC practices — the work of turning a method that runs in one laboratory into results that are comparable across many.
What sets my work apart is depth in lipid biology — one of the fastest-growing areas in drug discovery and precision medicine — combined with the strategic and leadership experience to translate that science into portfolio-level decisions.
I also hold an adjunct faculty position at Georgetown University, where I lead NIH- and Alzheimer's Association-funded research and mentor the next generation of translational scientists.
